RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)
Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and
